Possible targets for nonimmunosuppressive therapy of graves' orbitopathy

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 7, 2014, Pages

  Zhang, Lei ^a   Grennan Jones, F ^a   Draman, M S ^a   Lane, C ^b   Morris, D ^b   Dayan, C M ^a   Tee, A R ^a   Ludgate, M ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONAN SYNTHASE; HYALURONIC ACID; LIPOPROTEIN LIPASE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; SOMATOMEDIN C RECEPTOR; SYNTHETASE; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ADIPOGENESIS; ARTICLE; BIOACCUMULATION; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; DRUG TARGETING; ENDOCRINE OPHTHALMOPATHY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; HYALURONAN SYNTHASE GENE; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION;

ADIPOGENESIS; CELLS, CULTURED; CHROMONES; DRUG DISCOVERY; GENE EXPRESSION REGULATION; GRAVES OPHTHALMOPATHY; HUMANS; HYALURONIC ACID; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; QUINOXALINES; RECEPTOR, IGF TYPE 1; RECEPTORS, THYROTROPIN; SIGNAL TRANSDUCTION; THIAZOLIDINEDIONES;

EID: 84904036900     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-4182     Document Type: Article

References (40)

1. Bahn RS. Graves' ophthalmopathy. N Engl J Med. 2010;362:726-738.
2. Eckstein AK, Johnson KT, Thanos M, Esser J, Ludgate M. Current insights into the pathogenesis of Graves' orbitopathy. Horm Metab Res. 2009;41:456-464.
3. Ludgate M, Baker G. Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease. Clin Exp Immunol. 2002;127:193-198. (Pubitemid 34233922)
4. Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C, Heufelder AE. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab. 1998;83:998-1002. (Pubitemid 28496482)
5. Crisp MS, Lane C, Halliwell M, Wynford-Thomas D, Ludgate M. Thyrotropin receptor transcripts in human adipose tissue. J Clin Endocrinol Metab. 1997;82:2003-2005. (Pubitemid 127495225)
6. Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV, Fenzi G. Expression of thyrotropin-receptor mRNA in healthy and Graves' disease retro-orbital tissue. Lancet. 1993;342:337-338. (Pubitemid 23227563)
7. Khoo DH, Ho SC, Seah LL, et al. The combination of absent thyroid peroxidase antibodies and high thyroid-stimulating immunoglobulin levels in Graves' disease identifies a group at markedly increased risk of ophthalmopathy. Thyroid. 1999;9:1175-1180. (Pubitemid 30038925)
8. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS. A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. J Clin Endocrinol Metab. 2012;97:1681-1687.
9. Kumar S, Nadeem S, Stan MN, Coenen M, Bahn RS. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves' ophthalmopathy. J Mol Endocrinol. 2011;46:155-163.
10. Zhang L, Bowen T, Grennan-Jones F, et al. Thyrotropin receptor activation increases hyaluronan production in preadipocyte fibroblasts: contributory role in hyaluronan accumulation in thyroid dysfunction. J Biol Chem. 2009a;284:26447-26455.
11. Zhang L, Grennan-Jones F, Lane C, Rees DA, Dayan CM, Ludgate M. Adipose tissue depot-specific differences in the regulation of hyaluronan production of relevance to Graves' orbitopathy. J Clin Endocrinol Metab. 2012;97:653-662.
12. Gianoukakis AG, Douglas RS, King CS, Cruikshank WW, Smith TJ. Immunoglobulin G from patients with Graves' disease induces interleukin-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T-cell infiltration of the thyroid in autoimmune disease. Endocrinology. 2006;147:1941-1949.
13. Minich WB, Dehina N, Welsink T, et al. Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab. 2013;98:752-760.
14. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16:251-257. (Pubitemid 24111622)
15. Varewijck AJ, Boelen A, Lamberts SW, et al. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab. 2013;98:769-776.
16. Hansson HA, Petruson B, Skottner A. Somatomedin C in pathogenesis of malignant exophthalmos of endocrine origin. Lancet. 1986;1:218-219. (Pubitemid 16135552)
17. Krassas GE, Pontikides N, Kaltsas T, et al. Free and total insulin-like growth factor (IGF)-I, -II, and IGF binding protein-1, -2, and -3 serum levels in patients with active thyroid eye disease. J Clin Endocrinol Metab. 2003;88:132-135. (Pubitemid 36115154)
18. Wiersinga WM. Autoimmunity in Graves' ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab. 2011;96(8):2386-2394.
19. Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci. 2006;47:5197-5203. (Pubitemid 46723765)
20. Gillespie EF, Smith TJ, Douglas RS. Thyroid eye disease: towards an evidence base for treatment in the 21st century. Curr Neurol Neurosci Rep. 2012;12:318-324.
21. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol. 2007;156:33-40. (Pubitemid 46553901)
22. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655-1657. (Pubitemid 34579158)
23. Bell A, Grunder L, Sorisky A. Rapamycin inhibits human adipocyte differentiation in primary culture. Obes Res. 2000;8:249-254.
24. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28:1075-1083.
25. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269:5241-5248.
26. Scavo LM, Karas M, Murray M, Leroith D. Insulin-like growth factor-I stimulates both cell growth and lipogenesis during differentiation of human mesenchymal stem cells into adipocytes. J Clin Endocrinol Metab. 2004;89:3543-3553. (Pubitemid 38951933)
27. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab. 2004;89:5076-5080. (Pubitemid 39391451)
28. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol. 2008;181:4397-4405.
29. Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. 2009;150:519-529.
30. Van Sande J, Lejeune C, Ludgate M, et al. Thyroid stimulating immunoglobulins, like thyrotropin activate both the cyclic AMP and the PIP2 cascades in CHO cells expressing the TSH receptor. Mol Cell Endocrinol. 1992;88:R1-R5.
31. Zhang L, Paddon C, Lewis MD, Grennan-Jones F, Ludgate M. Gsalpha signalling suppresses PPARγ2 generation and inhibits 3T3-L1 adipogenesis. J Endocrinol. 2009b;202:207-215.
32. Sakaue H, Ogawa W, Matsumoto M, et al. Posttranscriptional control of adipocyte differentiation through activation of phosphoinositide 3-kinase. J Biol Chem. 1998;273:28945-28952. (Pubitemid 28507588)
33. Yu W, Chen Z, Zhang J, et al. Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem. 2008;310:11-18.
34. Kato Y, Ozaki N, Yamada T, Miura Y, Oiso Y. H-89 potentiates adipogenesis in 3T3-L1 cells by activating insulin signaling independently of protein kinase A. Life Sci. 2007;80:476-483. (Pubitemid 46013907)
35. Li F, Wang D, Zhou Y, et al. Protein kinase A suppresses the differentiation of 3T3-L1 preadipocytes. Cell Research. 2008;18:311-323. (Pubitemid 351206167)
36. Turcu AF, Kumar S, Neumann S, et al. A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. J Clin Endocrinol Metab. 2013;98:2153-2159.
37. Starkey KJ, Janezic A, Jones G, Jordan N, Baker G, Ludgate M. Adipose thyrotrophin receptor expression is elevated in Graves' and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo. J Mol Endocrinol. 2003;30:369-380. (Pubitemid 36722625)
38. Valyasevi RW, Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab. 1999;84:2557-2562.
39. Barak Y, Heroman WJ, Tezel TH. The past, present, and future of exudative age-related macular degeneration treatment. Middle East Afr J Ophthalmol. 2012;19:43-51.
40. Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res. 2008;68:9551-9557.